SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT
Minorsol solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of Minorsol solution for infusion contains:
Sodium chloride 6.429 mg
Potassium chloride 0.298 mg
Calcium chloride dihydrate 0.147 mg
Magnesium chloride hexahydrate 0.203 mg
Sodium acetate trihydrate 4.082 mg
Glucose monohydrate 11.0 mg
(equivalent to Glucose 10.0 mg)

equivalent to:
Na⁺ 140 mmol/l;
K⁺ 4 mmol/l;
Ca²⁺ 1 mmol/l;
Mg²⁺ 1 mmol/l;
Cl⁻ 118 mmol/l;
Acetate ions 30 mmol/l;
Glucose 55.5 mmol/l

Total cation/anion content 148 mval/l each, glucose 10 mg/ml.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Solution for infusion.
A clear, colourless to slightly yellow aqueous solution.
pH: 5.3–5.7
Theoretical osmolarity: 351 mOsmol/l
Titration acidity: to pH 7.4 ≤ 5 mmol/l
Energy content: 168 kJ/l (40 kcal/l)
Carbohydrate content: 10 g/l

4 CLINICAL PARTICULARS

4.1 Therapeutic indications
Minorsol is indicated for paediatric patients such as neonates (0 to ≤ 28 days), infants (28 days to ≤ 2 years), children (2 to ≤ 12 years), and adolescents (12 to ≤ 14 years) as follows:

– Perioperative plasma-isotonic fluid and electrolyte replacement with partial coverage of carbohydrate requirements,
– Short-term intravasal volume replacement,
– Treatment of isotonic dehydration,
– Use as carrier solution for compatible electrolyte concentrates and medicinal products.

4.2 Posology and method of administration
Posology

Paediatric population

The dosage in perioperative intravenous infusion therapy depends on the fluid, electrolyte, and glucose requirements:
During the first hour e.g. 10 – 20 ml/kg/hr, and thereafter for regulation of the infusion rate according to basic and correction requirements with monitoring of relevant cardiovascular and laboratory parameters.

For fluid requirements the following reference values apply:

Neonates (0 to ≤ 28 days), infants (28 days to ≤ 1 year):
100 – 140 ml/kg body mass and day

Infants aged 1 to ≤ 2 years:
80 – 120 ml/kg body mass and day

Children aged 2 to ≤5 years:
80 – 100 ml/kg body mass and day

Children aged 5 to ≤10 years:
60 – 80 ml/kg body mass and day

Children aged 10 to ≤12 years and adolescents aged 12 to ≤14 years:
50 – 70 ml/kg body mass and day

For the treatment of isotonic dehydration in the paediatric population the rate of infusion and the daily dose should be determined individually according to the nature and severity of the electrolyte and water imbalance by monitoring the relevant cardiovascular and laboratory parameters.

For short-term intravasal volume replacement the dosage should be determined individually according to the fluid needs.

If Minorsol is used in combination with other solutions for infusion the current guidelines on the total fluid supply for the relevant age group should be considered upon dosage calculation.

The individual water, electrolyte, and carbohydrate requirements should be calculated and replaced accordingly; in particular, pre-term and underweight neonates, but also in all other exceptional therapeutic situations. Balancing needs to be more exact the pre-term, younger, and underweight the patient is.

Method of administration
For intravenous use.

Duration of administration
The duration of administration depends on the patients fluid and electrolyte requirements.

4.3 Contraindications
- Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1,
- Status of hyperhydration.
4.4 **Special warnings and precautions for use**

Monitoring of electrolyte and fluid status as well as the acid-base balance is necessary.

Particularly careful risk-benefit assessment is required when this medicinal product is used in patients with pre-existing hyperglycaemia and metabolic alkalosis because the use of this medicinal product can deteriorate such conditions. In this case, it is preferable to use similar electrolyte-containing solutions for infusion without glucose and/or acetate, if possible. In addition, in this patient group closer monitoring, particularly, blood glucose level and acid-base balance as well as electrolyte balance is required in order to detect resulting risks at an early stage.

Caution is required specifically in neonates and infants because the risk of developing lactic acidosis cannot be ruled out when using acetate as contained in this medicinal product in very rare disorders of acetate metabolism. These very rare disorders of acetate metabolism may appear for the first time when administering this medicinal product.

Minorsol should be used in paediatric patients with congenital disturbance of lactate utilisation after a careful risk-benefit-balance only.

Controls of blood glucose levels are required postoperatively, post-traumatically and in other disorders of glucose tolerance (hyperglycaemia).

Caution is required in case of hypernatraemia, hyperkalaemia, and hyperchloremia.

4.5 **Interaction with other medicinal products and other forms of interaction**

There are no known interactions with other medicinal products.

4.6 **Fertility, pregnancy and lactation**

Minorsol is intended for use in the paediatric population (0 day to ≤14 years) only.

4.7 **Effects on ability to drive and use machines**

Not relevant.
4.8 Undesirable effects
As with all medicinal products for intravenous use, local site reactions associated with the method of administration cannot be excluded. The frequency of such reactions is not known (cannot be estimated from the available data). Local site reactions include febrile response, infections at the site of injection, venous thrombosis, phlebitis and extravasation extending from the site of injection.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard.

4.9 Overdose
Overdose may lead to hyperhydration and hyperglycaemia.

Treatment:
Interruption of the infusion, renal elimination should be accelerated, and administration of insulin, where appropriate.

For the intended use, no disturbances of electrolyte balance, osmolarity or acid-base balance are expected based on the composition of this medicinal product.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutical group: Solutions affecting the electrolyte balance, electrolytes and carbohydrates, ATC code: B05BB02

Pharmacodynamic effects
Minorsol is an electrolyte solution for paediatric patients that has been adjusted in its most important cation composition to the respective plasma concentration and is used for the correction of fluid and electrolyte disturbances. The solution has been adapted in its composition to the typical metabolic changes occurring in children during surgery and anaesthesia. The supply of electrolytes restores or maintains normal osmotic conditions in the extra- and intracellular compartments. In addition, the solution also contains 10 mg/ml carbohydrates as glucose.

Acetate is oxidised and has an alkalescent effect. Administration of Minorsol initially leads to replenishment of the interstitial space that accounts for approximately two-
thirds of the extracellular compartment. Approximately one-third of the supplied
volume remains in the intravascular space only. Therefore, the solution only has a
short-term haemodynamic effect.

5.2 Pharmacokinetic properties
Distribution and Biotransformation
Upon infusion, glucose is first distributed intravascularly and then is taken up into the
intracellular compartment.

Metabolism
Glucose, as a natural substrate of the cells in the organism, is ubiquitously
metabolised. Under physiological conditions it is the most important energy-
supplying carbohydrate with a caloric value of approximately 17 kJ/g or 4 kcal/g.
Central nervous system tissues, erythrocytes and renal medulla are among others the
obligatory glucose users. The normal fasting concentration of blood glucose range is
50 – 95 mg/100 ml or 2.8 – 5.3 mmol/l.

Glucose serves the formation of glycogen as the body’s carbohydrate reserve and
undergoes glycolysis to pyruvate or lactate for energy production in the cells. Glucose
also enables the maintenance of the blood glucose level and the biosynthesis of
important components of the organism. Insulin, glucocorticoids, and catecholamines
are mainly involved in hormonal regulation of the blood glucose level.

By glycolysis, glucose is metabolised to pyruvate or lactate. Lactate can be partially
re-introduced into the glucose metabolism (CORI cycle). Under aerobic conditions
pyruvate is completely oxidised to carbon dioxide and water. The final products of
this complete oxidation of glucose are eliminated via the lungs (carbon dioxide) and
the kidneys (water).

A precondition for optimal utilisation of supplied glucose is a normal electrolyte and
acid-base status. Particularly, acidosis can be a sign of impaired oxidative
metabolism.

There is a strong correlation between electrolyte and carbohydrate metabolism which
particularly affects potassium. Utilisation of glucose is associated with increased
potassium requirements. If this relationship is not taken into account considerable
disturbances of potassium metabolism may occur which can lead to massive cardiac
arrhythmias amongst other conditions.

Under pathological metabolic conditions impairment of glucose utilisation (glucose
intolerances) may occur. These include primarily diabetes mellitus as well as the
hormonally-induced decrease of glucose tolerance resulting from metabolic stress
(e.g. intra and post-surgery, serious illnesses, injuries) that may cause hyperglycaemia
even without exogenous substrate supply. Hyperglycaemia – depending on the
severity – may lead to osmotically based loss of fluid via the kidneys resulting in
hypertonic dehydration, hyperosmolar disturbances and even hyperosmolar coma.
Excessive supply of glucose, in particular, in the course of a post-aggression syndrome, can considerably increase the disturbance of glucose utilisation and contribute to enhanced conversion of glucose to fat resulting from impaired oxidative glucose utilisation. This in turn may be associated with an increased carbon dioxide burden of the organism (problems with weaning from respirator) and additional fat infiltration in the tissues, specifically in the liver. Patients with intracranial injury and brain oedema possess a particular risk to disturbances of glucose homeostasis. In these patients, even slight disturbances of the glucose concentration and the associated increase in plasma (serum) osmolality can contribute to a significant increase of cerebral injury.

Upon infusion acetate is first distributed intravascularly and then is taken up into the interstitial compartment. Under physiological conditions acetate is converted to bicarbonate and carbon dioxide. The plasma bicarbonate and acetate concentrations are regulated by the kidneys; the carbon dioxide plasma concentration by the lungs.

Elimination
In healthy subjects, there is practically no renal elimination of glucose. In pathological metabolic situations (e.g. diabetes mellitus, post-aggression symptom) that are accompanied by hyperglycaemia (blood glucose concentrations above 120 mg/100 ml or 6.7 mmol/l) glucose is also eliminated via the kidneys (glucosuria) when the maximum tubular transport capacity (180 mg/100 ml or 10 mmol/l) is exceeded.

5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans others than those included in other sections of this text. Electrolytes and glucose contained in Minorsol are physiological components of animal and human plasma. Toxic effects are unlikely to occur at therapeutic doses.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Hydrochloric acid 37 % (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
6.2 Incompatibilities

Incompatibility of the medicinal product to be added to Minorsol must be assessed before addition. In general, it can be stated that the following medicinal products (groups) must not be mixed with Minorsol:

– Medicinal products that might form hardly soluble precipitations with the constituents of the solution. (The preparation contains Ca2+ ions. Precipitation may occur with the addition of inorganic phosphate, hydrogen carbonate/carbonate or oxalate.),

– Medicinal products that are not stable in an acid pH-range or do not exhibit optimum efficacy or decompose,

– Minorsol must not be mixed with other medicinal products or solutions for parenteral nutrition for which compatibility has not been tested.

– Solutions for infusion that contain glucose must not be administered simultaneously through the same infusion equipment with blood because of the possibility of pseudo-agglutination.

6.3 Shelf life

3 years

Use immediately after first opening.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C, unless opening and storage have taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Minorsol is available in 100 ml, 250 ml, and 500 ml low-density polyethylene bottles (KabiPac) as primary packaging closed with a polyethylene or polyethylene/polypropylene cap containing a polyisoprene stopper.

Pack sizes:

40 x 100 ml bottles

20 x 250 ml bottles
10 x 500 ml bottles

Not all pack sizes may be marketed.

6.6 Special precautions for disposal
Use only if the solution is clear, without visible particles and if the container is undamaged.

For single use only.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited
Cestrian Court,
Eastgate Way,
Manor Park,
Runcorn,
Cheshire,
WA7 1NT
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)
PL 08828/0257

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
08/06/2016

10 DATE OF REVISION OF THE TEXT
08/06/2016